Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2015-08-11 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于召开2015年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about the convening of the 2015 second extraordinary general meeting of shareholders, detailing the meeting date, voting methods, agenda items, registration procedures, and other logistical information. It does not contain financial statements, audit results, or detailed management discussion. It is an announcement related to a shareholder meeting rather than the meeting materials or results themselves. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2015-08-11 Chinese
重大资产重组事项投资者说明会召开情况的公告
Investor Presentation Classification · 90% confidence The document is an announcement about an investor conference call regarding a major asset restructuring (重大资产重组事项投资者说明会召开情况的公告). It details the company's communication with investors about the ongoing asset acquisition and restructuring plans, including Q&A from investors and company responses. The document does not contain financial statements or detailed financial data but rather a summary of the investor meeting and explanations about the restructuring progress. The document length is relatively short (2453 characters), and it serves as a communication about the event rather than the event materials themselves. This fits the description of an Investor Presentation (IP) or possibly a Regulatory Filing (RNS). However, since it is specifically about an investor explanation meeting and includes Q&A, it aligns best with an Investor Presentation (IP) rather than a general regulatory announcement. Therefore, the most appropriate classification is Investor Presentation (IP).
2015-08-10 Chinese
重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the progress of a major asset restructuring (重大资产重组进展公告). It discusses the company's stock suspension due to the ongoing major asset reorganization, including acquisition plans and regulatory approvals. The text does not contain financial statements or detailed financial data but rather updates on the status of the restructuring process and stock trading suspension. The document length is short (1127 characters), and it serves as a progress update rather than a full report or financial disclosure. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as major asset restructurings.
2015-08-07 Chinese
关于与嘉兴会凌叁号投资合伙企业（有限合伙）签署购买资产意向书的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a letter of intent for an asset purchase between Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. and Jiaxing Huiling No. 3 Investment Partnership. It details the parties involved, definitions of terms, transaction objectives, pricing principles, termination conditions, breach liabilities, dispute resolution, and the impact on the company. There is no financial data, no full report, no audit, no earnings release, or other detailed financial statements. The document is a formal announcement of a transaction intention, which fits best under Capital/Financing Update (CAP) as it relates to a significant investment and asset acquisition intention. The document length is short (1968 characters), but it is not merely a report publication announcement or a regulatory filing. Therefore, the classification is CAP with high confidence.
2015-08-06 Chinese
关于重大资产重组事项召开投资者说明会预告公告
Investor Presentation Classification · 95% confidence The document is an announcement about an upcoming investor meeting regarding a major asset restructuring. It specifies the date, time, and platform for the investor explanation meeting and mentions that the company is currently in the process of a major asset reorganization. The document does not contain financial statements or detailed financial data but serves to inform investors about the meeting and facilitate communication. It is not a full report, earnings release, or regulatory filing but an announcement of an investor presentation event. Therefore, the most appropriate classification is 'Investor Presentation' (IP). The document length is short and focused on the meeting announcement, not the report itself, so it is not a report publication announcement (RPA).
2015-08-05 Chinese
重大资产重组进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of a major asset restructuring (重大资产重组进展公告) by the company 中源协和细胞基因工程股份有限公司. It discusses the company's stock suspension due to the ongoing major asset restructuring, the complexity of the process involving overseas listed company privatization or acquisition, and the expected continuation of the suspension. The document is a regulatory announcement updating shareholders and the market on the status of the restructuring and stock suspension, without containing financial statements or detailed financial data. It is not a full report like an Annual Report or Interim Report, nor is it a merger filing or proxy statement. Given the nature and length (798 characters), it fits best as a Regulatory Filing (RNS) which covers general regulatory announcements and compliance documents that do not fit other categories.
2015-07-31 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.